查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
齊拉西酮全球市場-2022-2029
市場調查報告書
商品編碼
1129251

齊拉西酮全球市場-2022-2029

Global Ziprasidone Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

預計全球精神疾病的流行將推動市場增長。

根據世界衛生組織 (WHO) 的說法，精神分裂症會導致精神病，與相當大的殘疾有關，並且會影響生活的所有領域，包括個人、家庭、社會、教育和職業功能。它一直存在。據說精神分裂症影響全球約 2400 萬人，即 300 人中有 1 人（0.32%）。在成人中，這一比例為 222 分之 1（0.45%）。它不像許多其他精神疾病那樣普遍。因此，某些精神疾病的增加增加了對該藥的需求，該藥主要以齊拉西酮治療。

此外，推薦使用這種藥物，因為它具有明顯的即時效果和立即緩解症狀。此外，Reddy 博士於 2020 年 3 月 17 日宣布推出甲磺酸齊拉西酮，旨在通過增加藥房的價值使醫療保健更實惠。因此，從上述陳述來看，預計將在預測期內推動市場。

與齊拉西酮相關的副作用預計會阻礙市場增長。

齊拉西酮是一種會增加體重增加、糖尿病和高膽固醇風險的藥物。此外，如果患者有心律失常、長 QT 綜合徵或不受控制的心力衰竭病史，則不鼓勵使用齊拉西酮，從而減少對該產品的需求。齊拉西酮的低需求是由於呼吸道感染、錐體外系症狀、靜坐不能、視力模糊、頭暈、嘔吐、頭痛和噁心等副作用。同樣，氟□啶醇、奎硫平和阿立□唑等更有效替代品的出現將減少齊拉西酮的市場需求。此外，使用該產品引起的代謝綜合徵的健康危害預計將阻礙預測期內的市場增長。

行業分析

齊拉西酮市場根據各種行業因素（包括供應鏈分析、定價分析等）對市場進行深入分析。

COVID-19 影響分析

COVID-19 大流行對醫療保健系統和市場產生了適度影響。 COVID-19 影響人們的心理健康和生活質量。 COVID-19 會引起恐慌、焦慮、抑鬱和失眠，尤其是在患者和醫護人員中。可能會為 COVID-19 患者開具精神科藥物。此外，一些 COVID-19 患者出於各種原因使用精神科藥物。因此，精神科藥物和用於治療 COVID-19 的藥物之間存在藥物相互作用 (DDI) 的風險。細胞色素 P450 系統負責幾種精神藥物的代謝。

另一方面，大流行會破壞供應鍊和流程。許多公司將轉移到其他地區以確保產品可用性並保護其供應鏈。因此，從上面這句話來看，市場受到了影響，預計隨著經濟活動的恢復，市場將迅速獲得牽引力。

全球齊拉西酮市場報告將提供對大約 45 多個市場數據表、40 多個數字和 180 頁的訪問。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因子
    • 驅動程序
      • 預計全球精神疾病的流行將推動市場增長。
    • 限制因素
      • 與齊拉西酮相關的副作用預計會阻礙市場增長。
    • 市場機會
    • 影響分析

第五章行業分析

  • 供應鏈分析
  • 定價分析
  • 未滿足的需求分析
  • 管道分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章給藥途徑

  • 口服膠囊
  • 肌肉注射
  • 其他

第 8 章按應用程序

  • 精神分裂症
  • 躁鬱症
  • 激動
  • 其他

第 9 章按銷售渠道

  • 醫院藥房
  • 在線藥店
  • 零售店
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 產品基準
  • 值得關注的重點公司列表

第 12 章公司簡介

  • Pfizer Inc
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Sandoz AG
  • Lupin Pharmaceuticals, Inc.
  • Mylan Pharmaceuticals
  • Apotex
  • Dr. Reddy's laboratories Ltd.
  • Wockhardt
  • Aurobindo Pharma USA

第 13 章齊拉西酮-DataM 全球市場

簡介目錄
Product Code: DMPH5804

Market Overview

The Ziprasidone Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Ziprasidone, commonly known as Geodon, is an atypical antipsychotic of the second generation that is used to treat schizophrenia and bipolar disorder, among other things. The pills include hydrochloride salt and ziprasidone hydrochloride, which rebalances dopamine and serotonin in the brain to improve mood and behavior.

Market Dynamics

The increasing prevalence of mental disorders worldwide is expected to drive market growth.

According to the World Health Organization, Schizophrenia causes psychosis, is associated with considerable disability and may affect all areas of life, including personal, family, social, educational, and occupational functioning. Schizophrenia affects around 24 million people globally or one in every 300 people (0.32 percent). Adults have a rate of 1 in 222 (0.45 percent). It is not as widespread as many other mental illnesses. Therefore, the demand for the medication has increased due to an increase in certain mental health conditions, which are largely treated with Ziprasidone.

Furthermore, the medicine is recommended because of the immediate effect visible when delivering the dose, resulting in immediate alleviation. Moreover, Dr. Reddy's announced the launch of Ziprasidone Mesylate on March 17, 2020, intending to make healthcare more affordable by giving value to the pharmacy. Thus, from the above statements, the market is expected to drive in the forecast period.

Side effects associated with ziprasidone are expected to hamper the market growth.

Ziprasidone is a medicine that increases the risk of weight gain, diabetes, and high cholesterol. Also, using ziprasidone is not recommended if the patient has a history of heart rhythm disorders, long QT syndrome, or uncontrolled heart failure, which diminishes the product's demand. Ziprasidone's low demand is due to side effects such as respiratory tract infections, extrapyramidal symptoms, akathisia, altered eyesight, dizziness, vomiting, headache, and nausea. Likewise, the availability of more effective alternatives like haloperidol, quetiapine, and aripiprazole diminishes market demand for ziprasidone. The metabolic syndrome health hazards associated with utilizing the product will hamper the market growth in the forecast period.

Industry Analysis

The ziprasidone market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. COVID-19 has an impact on people's mental health and quality of life. COVID-19 induces panic, anxiety, depression, and insomnia, particularly in patients and health care workers. Patients with COVID-19 may be prescribed mental medications. In addition, some COVID-19 patients have been using psychiatric medicines for various reasons. As a result, there is a risk of drug-drug interaction (DDI) between psychiatric medicines and drugs used to treat COVID-19. The cytochrome P450 system is responsible for the metabolism of several psychiatric medications.

In contrast, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of economic activities.

Segment Analysis

Oral Capsules segment is expected to hold the largest market share in ziprasidone market

The oral capsules segment is expected to dominate in 2021. The segment benefits because the capsules have been approved by the US Food and Drug Administration (FDA) for long-term treatment of individuals with bipolar disorder due to their effectiveness and patient tolerability. The simplicity of long-term usage required due to the chronic nature of the sickness and the requirement of lesser doses of the medicine to be given at different times to improve the efficacy of the treatment also contribute to the demand. Oral capsules are less likely to cause an overdose. Oral capsules for Ziprasidone are less expensive than injections, making the medication more accessible and increasing demand. Thus, from the above statements, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global ziprasidone market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of bipolar disorders, high adoption of ziprasidone drugs, product launches and acquisitions by the market key players and rising clinical trials in the region are some factors the market is expected to boost in the forecast period. For instance, according to the National Institute of Mental Health, Bipolar disorder affects approximately 5.7 million adult Americans, or about 2.6% of the U.S. age 18 and older every year. Moreover, bipolar illness affects an equal number of men and women and affects people of all ages, races, ethnic groups, and social classes. Additionally, Upjohn, a part of Pfizer, announced the completion of the Phase 3 pediatric clinical trial for Geodon on November 10, 2020. (ziprasidone). The study looked at the efficacy and safety of ziprasidone in children and adolescents with bipolar I disorder. Thus, from the above statements, the North American region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the ziprasidone market are Pfizer Inc., Sandoz AG, Lupin Pharmaceuticals, Inc., Mylan Pharmaceuticals, Apotex, Dr. Reddy's laboratories Ltd. , Wockhardt, Aurobindo Pharma USA.

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

Product Portfolio:

GEODON (ziprasidone HCl): GEODON Capsules are indicated for treating schizophrenia in adults, acute treatment in adults as monotherapy of manic or mixed episodes associated with bipolar I disorder, and maintenance treatment of bipolar I disorder as an adjunct to lithium or valproate in adults.

The global ziprasidone market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing prevalence of mental disorders worldwide is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with ziprasidone are expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs
  • 5.4. Pipeline Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Route of Administration

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 7.1.2. Market Attractiveness Index, By Route of Administration Segment
  • 7.2. Oral Capsules*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Intramuscular Injection
  • 7.4. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application Segment
  • 8.2. Schizophrenia*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Bipolar Mania
  • 8.4. Agitation
  • 8.5. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Online Pharmacies
  • 9.4. Retail Pharmacies
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Route of Administration
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Pfizer Inc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Sandoz AG
  • 12.3. Lupin Pharmaceuticals, Inc.
  • 12.4. Mylan Pharmaceuticals
  • 12.5. Apotex
  • 12.6. Dr. Reddy's laboratories Ltd.
  • 12.7. Wockhardt
  • 12.8. Aurobindo Pharma USA

LIST NOT EXHAUSTIVE

13. Global Ziprasidone Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us